

Dyslipidemia in Egyptian Children and Adolescents with Type 1 Diabetes Mellitus

Thesis

Submitted for Partial Fulfillment of Master Degree in Pediatrics

By

Nanees Ateya Aly Abd Allah Al wakeel

M.B.B.Ch.

Faculty of Medicine, Cairo University

Supervised By

Prof. Dr. Mona Mamdouh Abdel ghafour

Professor of Pediatrics

Faculty of Medicine, Cairo University

Prof. Dr. Sahar Abdel atty Sharaf

Professor of Clinical and Chemical Pathology

Faculty of Medicine, Cairo University

Dr. Hend Mehawed Abdel latif

Lecturer of pediatrics

Faculty of Medicine, Cairo University

Department of pediatrics

Faculty of Medicine

Cairo University

2013

ACKNOWLEDGEMENT

First and foremost I would like to thank ALLAH to whom I relate any success I have reached and might reach in the future.

Words are short to express my deep sense of gratitude towards Prof. Dr. Mona Mamdouh Hassan, Professor of Pediatrics and Pediatric Endocrinology, Faculty of Medicine, Cairo University, for her valuable guidance, constant support and encouragement throughout the work. I doubt that I will ever be able to convey my appreciation fully, but I owe her my eternal gratitude.

I wish to express my sincere thanks to Prof. Dr. Sahar Abdel atty Sharaf, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her generous help, valuable directions, kind advice and remarkable suggestions to fulfill this work.

I would like to gratefully acknowledge Dr. Hend Mehawed Abdel latif, Lecturer of pediatrics, Faculty of Medicine, Cairo University, for her meticulous supervision, useful comments, remarks and engagement through the learning process of this master thesis.

My special acknowledgement to Prof. Dr. Magdy Ibrahim Mostafa, Professor of Obstetrics & Gynecology and Director of Research & Biostatistics Unit, MEDC, Faculty of Medicine, Cairo University, for the precise statistics of this work.

Last but not least, I would like to dedicate this work to the soul of my parents and to my brothers, sister & aunt. I owe everything to them.

ABSTRACT

Background: Dyslipidemia is a significant CVD risk factor in persons with diabetes. CVD is the leading cause of death in people with T1DM. **Objective:** To evaluate the frequency, pattern and relations of dyslipidemia in children and adolescents with T1DM in DEMPU. **Method:** In this cross-sectional study, fasting lipid profile of 60 patients aged ≥ 9 years with T1DM was measured and compared with that of 39 healthy age and sex matched children. **Results:** Dyslipidemia was found in 65.0% of patients compared with 28.2% of the control group with a statistically significant difference ($p < 0.001$). Fifty percent of the patients had elevated LDL-C levels with a mean of 102.0 ± 34.4 mg/dl and a positive significant correlation with BMI. There were positive significant correlations between the dyslipidemia and female sex and activity. The most frequent type of dyslipidemia was high LDL-C and low HDL-C. Dyslipidemia was found regardless the family history, degree of glycemic control, BMI SDS, diabetes duration and dietary habits. **Conclusion:** Dyslipidemia in children and adolescents with T1DM was significantly more frequent than in healthy control subjects. So, screening and management may be considered especially in diabetic females. LDL-C is the 'cornerstone' for assessment of lipoprotein-related CVD risk. Activity is important for prevention of dyslipidemia.

Key Words: Type 1 diabetes mellitus, dyslipidemia, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, cardiovascular disease risk, activity, body mass index, children and adolescents.

CONTENTS

	Page
List of abbreviations	I
List of tables	III
List of figures	V
Introduction	VII
Aim of work	IX
Review of literature.....	1
Chapter 1: Type 1 diabetes mellitus.....	1
Chapter 2: Lipids and lipoproteins metabolism.....	37
Chapter 3: Dyslipidemia in type 1 diabetes mellitus.....	51
Subjects and methods.....	69
Results.....	78
Discussion.....	126
Summary.....	138
Conclusion.....	141
Recommendations.....	142
References.....	143
Appendix.....	171
Arabic summary.....	

LIST OF ABBREVIATIONS

ACEI	Angiotensin converting enzyme inhibitors
ADA	American Diabetes Association
AIP	Atherogenic Index of Plasma
Apo A	Apoprotein A
Apo B	Apoprotein B
Apo C	Apoprotein C
Apo E	Apoprotein E
BG	Blood glucose
BMI	Body mass index
BP	Blood pressure
CAD	Coronary artery disease
CETP	Cholesterol ester transfer protein
CM	Chylomicrons
CSII	Continuous Subcutaneous Insulin Infusion
CVD	Cardiovascular disease
DBP	Diastolic blood pressure
DCCT	Diabetes Control and Complications Trial
DEMPU	Diabetes Endocrine and Metabolism Pediatric Unit
DKA	Diabetic ketoacidosis
DM	Diabetes mellitus
FBG	Fasting blood glucose
FER _{HDL}	Fractional esterification rate of cholesterol
FFA	Free fatty acid
GAD	Glutamic acid decarboxylase
HbA1c	Glycosylated hemoglobin
HDL-C	High density lipoprotein-Cholesterol
HHS	Hyperglycemic hyperosmolar state
HLA	Human leukocyte antigen
HMG-CoA	Hydroxy methylglutaryl- Coenzyme A
HTGL	Hepatic triglyceride lipase
IA2	Tyrosine phosphatase autoantibodies
IAA	Insulin autoantibodies
ICA	Islet cell autoantibodies
IDF	International Diabetes Federation
IDL	Intermediate density lipoprotein
INS	Insulin gene
ISPAD	International Society for Pediatric and Adolescent Diabetes
LCAT	Lecithin cholesterol acyl transferase

List of abbreviations

LDL-C	Low density lipoprotein-Cholesterol
Lp (a)	Lipoprotein (a)
LPL	Lipoprotein lipase
MDI	Multiple Daily Injections
MS	Metabolic syndrome
PAD	Peripheral artery disease
PPBG	Postprandial blood glucose
SAT	Subcutaneous abdominal adipose tissue
SBP	Systolic blood pressure
SD	Standard deviation
SDS	Standard deviation score
SMBG	Self-monitoring of blood glucose
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TC	Total cholesterol
TDEI	Total daily energy intake
TG	Triglycerides
TLC	Therapeutic Lifestyle Changes
VAT	Visceral adipose tissue
VLDL	Very low density lipoprotein
VNTR	Variable number of tandem repeats
WC	Waist circumference

LIST OF TABLES

Table No.	Title	Page
Table (1)	Clinical characteristics of type 1, type 2 and monogenic diabetes in children and adolescents	7
Table (2)	Aetiological classification of disorders of glycaemia	8
Table (3)	Criteria for the diagnosis of diabetes	14
Table (4)	Categories of increased risk for diabetes (prediabetes)	15
Table (5)	Factors determining the glycemic response to acute exercise	29
Table (6)	Action profiles of different insulin preparations	30
Table (7)	Characteristics of major lipoproteins	44
Table (8)	Recommendations for fasting lipid profile screening in children and adolescents (aged 2-18 years)	58
Table (9)	American Diabetes Association guidelines for lipoprotein goals and therapy in diabetic patients	59
Table (10)	Two-step approach to treatment of hypercholesterolemia	60
Table (11)	Lipid-modifying drugs	63
Table (12)	Cholesterol risk chart	68
Table (13)	Guidelines for calculating daily caloric needs	71
Table (14)	Definition and classification of hypertension in pediatric age	73
Table (15)	Assessment of the glycemic control according to the GLOBAL IDF/ISPAD GUIDELINE FOR DIABETES IN CHILDHOOD AND ADOLESCENCE	74
Table (16)	Age, age at onset of diabetes, diabetes duration and insulin dose of the study group	79
Table (17)	Frequency of parental consanguinity and family history of diabetes and cardiovascular risk in the study group	80
Table (18)	First presentation of diabetes, insulin type and injection sites of the study group	81
Table (19)	Values of anthropometric measures of the study group	83
Table (20)	Anthropometric measures of the study group	84
Table (21)	Blood pressure of the study group	86
Table (22)	Degree of glycemic control in the study group	87
Table (23)	Parameters of glycemic control and lipid profile of the study group	88
Table (24)	Degree and duration of activity in the study group	90
Table (25)	Diet analysis of the study group	91
Table (26)	Frequency of normal or increased daily caloric and fat intake in the study group	92
Table (27)	Parameters of lipid profile of cases and controls	94
Table (28)	Frequency of abnormal lipid concentrations in cases and controls	96

List of tables

Table (29)	Parameters of lipid profile of dyslipidemic and normolipidemic groups	97
Table (30)	Percentage of different types of dyslipidemia in the dyslipidemic group	99
Table (31)	Age, age at onset of diabetes, diabetes duration and insulin dose in dyslipidemic and normolipidemic groups	101
Table (32)	Gender, puberty and frequency of family history of diabetes and cardiovascular risk in dyslipidemic and normolipidemic groups	102
Table (33)	Anthropometric measures of dyslipidemic and normolipidemic groups	104
Table (34)	Values of anthropometric measures of dyslipidemic and normolipidemic groups	106
Table (35)	Blood pressure of dyslipidemic and normolipidemic groups	107
Table (36)	Parameters of glycemic control of dyslipidemic and normolipidemic groups	108
Table (37)	Degree of glycemic control in dyslipidemic and normolipidemic groups	109
Table (38)	Different lipoprotein risk ratios of dyslipidemic group	111
Table (39)	Degree and duration of activity in dyslipidemic and normolipidemic groups	112
Table (40)	Diet analysis of dyslipidemic and normolipidemic groups	114
Table (41)	Frequency of normal or increased daily caloric and fat intake in dyslipidemic and normolipidemic groups	115
Table (42)	Correlations of total cholesterol with age, duration of diabetes, insulin dose, body mass index, glycemic control parameters and diet	119
Table (43)	Correlations of triglycerides with age, duration of diabetes, insulin dose, body mass index, glycemic control parameters and diet	120
Table (44)	Correlations of high density lipoprotein-cholesterol with age, duration of diabetes, insulin dose, body mass index, glycemic control parameters and diet	121
Table (45)	Correlations of low density lipoprotein-cholesterol with age, duration of diabetes, insulin dose, body mass index, glycemic control parameters and diet	122
Table (46)	Correlations of body mass index with insulin dose, waist circumference, glycemic control parameters, diet and lipids	123
Table (47)	Correlations of body mass index (SDS) with insulin dose, waist circumference, glycemic control parameters, diet and lipids	124
Table (48)	Correlations of waist circumference with insulin dose, body mass index, glycemic control parameters, diet and lipids	125

LIST OF FIGURES

Figure No.	Title	Page
Figure (1)	How type 1 diabetes mellitus might arise	10
Figure (2)	Diabetic complications	16
Figure (3)	Fundus images of diabetic retinopathy	20
Figure (4)	Distribution of sensory loss in patient with severe chronic diabetic sensory polyneuropathy	21
Figure (5)	Food pyramid	24
Figure (6)	The insulin pump	31
Figure (7)	Isoprenoid biosynthetic pathway	41
Figure (8)	Exogenous and endogenous pathway of cholesterol	43
Figure (9)	Chylomicron	45
Figure (10)	Low density lipoprotein-Cholesterol molecule	46
Figure (11)	Outline of human lipoprotein metabolism	47
Figure (12)	Main effects of insulin on lipoprotein metabolism	50
Figure (13)	Oxidative modification hypothesis of atherosclerosis	54
Figure (14)	Diagnostic and therapeutic algorithm for children and adolescents with elevated low density lipoprotein-cholesterol	61
Figure (15)	Effect of exercise on lipid metabolism	62
Figure (16)	Gender distribution of the study group	79
Figure (17)	Percentage of family history of diabetes and cardiovascular risk in the study group	80
Figure (18)	Percentage of acute complications in the study group	82
Figure (19)	Mean values of anthropometric measures of the study group	83
Figure (20)	Distribution of body mass index (SDS) of the study group	84
Figure (21)	Percentage of central obesity in the study group	85
Figure (22)	Percentage of short stature in the study group	85
Figure (23)	Distribution of blood pressure of the study group	86
Figure (24)	Degree of glycemic control in the study group	87
Figure (25)	Mean values of glycemic control parameters of the study group	89
Figure (26)	Mean values of lipid profile parameters of the study group	89
Figure (27)	Degree of activity in the study group	90
Figure (28)	Mean carbohydrate, protein and fat (gm/day) in diet of study group	92
Figure (29)	Percentage of dyslipidemia in cases and controls	93
Figure (30)	Mean values of lipid profile parameters of cases and controls	95
Figure (31)	Percentage of abnormal lipid concentrations in cases and controls	96

List of figures

Figure (32)	Mean values of lipid profile in dyslipidemic and normolipidemic groups	98
Figure (33)	Percentage of different types of dyslipidemia in the dyslipidemic group	99
Figure (34)	Gender distribution of dyslipidemic and normolipidemic groups	100
Figure (35)	Mean age, age at onset of diabetes and diabetes duration (years) in dyslipidemic and normolipidemic groups	101
Figure (36)	Percentage of family history of diabetes and cardiovascular risk in dyslipidemic and normolipidemic groups	103
Figure (37)	Body mass index (SDS) of dyslipidemic and normolipidemic groups	105
Figure (38)	Percentage of central obesity and short stature in dyslipidemic and normolipidemic groups	105
Figure (39)	Mean body mass index and waist circumference of dyslipidemic and normolipidemic groups	106
Figure (40)	Blood pressure of dyslipidemic and normolipidemic groups	107
Figure (41)	Degree of glycemic control in dyslipidemic and normolipidemic groups	110
Figure (42)	Mean values of glycemic control parameters of dyslipidemic and normolipidemic groups	110
Figure (43)	Degree of activity in dyslipidemic and normolipidemic groups	112
Figure (44)	Mean carbohydrate, protein and fat in diet of dyslipidemic and normolipidemic groups	114
Figure (45)	Mean caloric intake (total, fat) in dyslipidemic and normolipidemic groups	115
Figure (46)	Percentage of normal or increased daily caloric intake in dyslipidemic and normolipidemic groups	116
Figure (47)	Percentage of normal or increased daily fat intake in dyslipidemic and normolipidemic groups	116

INTRODUCTION

AIM OF THE WORK

INTRODUCTION

Type 1 diabetes mellitus (T1DM) is the most common childhood endocrine disease (**Teles and Fornés, 2012**). The suggestion that there will be an epidemic of diabetes by 2025 and that we can therefore expect a massive increase in macrovascular disease has focused attention on the mechanisms by which diabetes promotes atherosclerosis to such an extent (**Tomkin, 2008**).

Diabetes is a major risk factor for cardiovascular disease (CVD). In patients with T1DM, atherosclerosis occurs earlier in life, leading to increased morbidity and mortality compared with those in the general population (**Guy et al., 2009**).

Coronary artery disease (CAD) is the leading cause of mortality in patients with T1DM (**Wadwa et al., 2005**). Cardio-metabolic risk factor management has evolved considerably with the continued emergence of new and thought-provoking evidence. As a result, the most recent clinical trials on glycemic control for macrovascular risk reduction are woven into concrete clinical practice guidelines in patients with diabetes (**Ali et al., 2010**).

Dyslipidemia is a preventable major risk factor for CVD. There are several studies that have evaluated dyslipidemia in patients with type 2 diabetes mellitus (T2DM), but dyslipidemia in patients with T1DM and especially young children with short duration of diabetes remains largely undiagnosed and undertreated (**Wadwa et al., 2005**) and (**Hamad and Qureshi, 2008**). It has been shown that the quantity of plasma lipids gives adequate information about the risk of complications. The intensity of dyslipidemia predicts macrovascular complication such as a CAD in patients with T1DM. Diabetic children and adolescents revealed significant disorder in lipid metabolism including both

qualitative and quantitative abnormalities of lipids (**Hamad and Qureshi, 2008**).

Dyslipidemia was defined by American Diabetes Association (ADA) as having low density lipoprotein-cholesterol (LDL-C) ≥ 100 mg/dl, high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl (males) & < 50 mg/dl (females), total cholesterol (TC) ≥ 200 mg/dl and triglycerides (TG) ≥ 150 mg/dl (**Wysham et al., 2012**). Dyslipidemia is present if one or more of these lipid or lipoprotein levels are abnormal (**Kwiterovich, 2008**).

LDL-C is a well-recognized risk factor for atherosclerosis-related diseases, in particular CAD. This is well illustrated in the multiple risk factor intervention trial by **Stamler et al. (1993)** where CAD death was positively correlated to plasma cholesterol level. Oxidized LDL-C may also stimulate secretion of cytokines and growth factors by endothelial cells, smooth muscle cells and macrophages. This results in complex changes in the arterial wall involving further attraction of macrophages, proliferation of smooth muscle cells and laying down of extracellular matrix, altogether completing the process of atherosclerosis. So, primary emphasis should be placed on LDL-C lowering, while interventions to lower the TG levels and raise HDL-C levels may also be very useful (**Chowdhury and Pandit, 2012**).

In addition, chronic hyperglycemia promotes the glycation of LDL-C, and both glycation and oxidation are believed to increase the atherogenicity of LDL-C. Both of these processes may impair function and/or enhance atherogenicity even in those with T1DM with a normal lipid profile (**John Mancini et al., 2013**). For these reasons, improvement in diabetic control leads to improvement in cardiovascular outcome in diabetes (**Tomkin, 2008**).

AIM OF THE WORK

The aim of this work is to evaluate the frequency and pattern of dyslipidemia in children and adolescents with type 1 diabetes mellitus (T1DM) following at the Diabetes Endocrine and Metabolism Pediatric Unit (DEMPU), Children's Hospital, Cairo University; and to study the relation of dyslipidemia to their age, age at onset and duration of diabetes, degree of glycemic control, insulin dose, body mass index (BMI), waist circumference (WC) and epidemiological risk factors including family history, diet and life-style.

**REVIEW
OF
LITERATURE**